Document is current
Any future updates will be listed below
-
Authors
Aarnoutse, Romy https://orcid.org/0000-0002-8713-9747
Ziemons, Janine https://orcid.org/0000-0002-4559-5488
Hillege, Lars E. https://orcid.org/0000-0001-7010-7610
de Vos-Geelen, Judith
de Boer, Maaike
Bisschop, Saskia M. P.
Vriens, Birgit E. P. J.
Vincent, Jeroen
van de Wouw, Agnes J.
Le, Giang N. https://orcid.org/0000-0001-6660-557X
Venema, Koen
Rensen, Sander S.
Penders, John
Smidt, Marjolein L.
- License Information
-
More Information
Article History
Received: 3 May 2021
Accepted: 5 July 2022
First Online: 29 July 2022
Competing interests
: J.d.V.G. has served as a consultant for Amgen, AstraZeneca, MSD, Pierre Fabre and Servier. All outside the submitted work. J.d.V.G., M.L.S. and R.A. have received institutional research funding from Servier. All outside the submitted work. M.d.B. received research funding from Roche, Novartis, Pfizer, Eisai and AstraZeneca outside this submitted work. M.d.B. received a travel grant from Roche outside this submitted work. The other authors declare no competing financial interest. The Kootstra Talent Fellowship partly financially supported this study. K.V. acknowledges support in funding from the Dutch Province of Limburg. All authors declare no competing non-financial interests.
